In the latest quarter, 4 analysts provided ratings for Delcath Systems (NASDAQ:DCTH), showcasing a mix of bullish and bearish perspectives.

Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $21.75, with a high estimate of $22.00 and a low estimate of $21.00. This current average is unchanged from the previous average price target.

Investigating Analyst Ratings: An Elaborate Study

The analysis of recent analyst actions sheds light on the perception of Delcath Systems by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

For valuable insights into Delcath Systems's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.

Stay up to date on Delcath Systems analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Delving into Delcath Systems's Background

Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

Delcath Systems: Financial Performance Dissected

Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.

Positive Revenue Trend: Examining Delcath Systems's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 2480.65% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.

Net Margin: Delcath Systems's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 16.64%, the company showcases strong profitability and effective cost management.

Return on Equity (ROE): Delcath Systems's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 29.21%, the company showcases efficient use of equity capital and strong financial health.

Return on Assets (ROA): Delcath Systems's ROA stands out, surpassing industry averages. With an impressive ROA of 5.68%, the company demonstrates effective utilization of assets and strong financial performance.

Debt Management: With a below-average debt-to-equity ratio of 0.36, Delcath Systems adopts a prudent financial strategy, indicating a balanced approach to debt management.

What Are Analyst Ratings?

Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

Breaking: Wall Street's Next Big Mover

Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.

This article was generated by Benzinga's automated content engine and reviewed by an editor.